Macrogenics (NASDAQ: MGNX) reported Q3 EPS of ($0.97), $0.17 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $12.45 million.

Cash, cash equivalents and marketable securities as of September 30, 2016, were $314.1 million, compared to $339.0 million as of December 31, 2015.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.